Mathieu Ferrari

Mathieu Ferrari has a strong background in therapeutic antibody development with experience in academic and industry settings. Currently holding the position of Senior Director at Autolus Ltd., Mathieu leads the antibody and protein engineering group in the discovery and characterization of protein binders for CAR-T cell therapeutics. With a Doctor of Philosophy in Experimental Medicine and Rheumatology, Mathieu has a particular focus on developing novel antibody-based therapies for targeted delivery in inflammatory disease conditions. Additionally, Mathieu has previously worked on research projects involving HIV-1 isolates and dendritic cell infection. Educationally, Mathieu holds a variety of degrees from institutions such as Queen Mary University of London and Sapienza Università di Roma.